Shopping Cart
Your Cart is Empty
Quantity:
Subtotal
Taxes
Shipping
Total
There was an error with PayPalClick here to try again
CelebrateThank you for your business!You should be receiving an order confirmation from Paypal shortly.Exit Shopping Cart

The Venture 17 Division Of Education



THE CONSERVATORY OF MEDICAL ARTS AND SCIENCES

XVII

THE SEARCHLIGHT MESSENGER

Blog

Venetoclax Shows Promise in Acute Myelogenous Leukemia

Posted on August 19, 2016 at 5:31 PM
Venetoclax monotherapy appears to improve outcomes in some patients with acute myelogenous leukemia (AML), according to a phase 2, single-arm study.

"This study included patients that were in categories that are difficult to treat - relapsed, refractory, and/or elderly and deemed medically unfit to receive induction therapy," Dr. Anthony Letai from Dana-Farber Cancer Institute in Boston told Reuters Health by email.

"The fact that some of these patients had leukemias that were relapsed or refractory to very tough regimens, including regimens that require multi-week inpatient hospital stays, but nonetheless responded to an oral outpatient therapy taken once a day was a very interesting result," he said.

Venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL) earlier this year.

Dr. Letai and colleagues investigated the efficacy and biological correlates of response in the first clinical study of venetoclax monotherapy in 32 patients with relapsed/refractory AML or untreated AML unfit for intensive therapy.

The objective response rate was 19% (six of 32), with two patients achieving a complete response and four achieving a complete response with incomplete blood count recovery. All objective responses were achieved by the week-4 assessment.

An additional 19% had antileukemic activity demonstrated by partial bone marrow response and incomplete hematologic recovery.



The six-month leukemia-free survival rate was 10% (median leukemia-free survival, 2.3 months), and the six-month overall survival estimate was 36% (median overall survival, 4.7 months), the researchers report in Cancer Discovery, online August 12.
At the time of this report, all patients had discontinued venetoclax: 29 due to progressive disease, one due to adverse event, one withdrew consent, and one proceeded to allogeneic hematopoietic stem cell transplant after achieving stable disease.

"Our data provide evidence that AML with IDH1/2 mutations exhibits BCL2 dependence and validates preclinical data that suggest suppression of cytochrome c oxidase activity in IDH1/2 mutant AML lowers the mitochondrial threshold to trigger apoptosis upon BCL2 inhibition," the researchers note. "However, activity observed in patients with wild-type IDH1/2 suggests targeting BCL2 with venetoclax should not be restricted to patients with mutations in IDH1/2."

Venetoclax monotherapy was generally well tolerated, although treatment-emergent adverse events were reported for all patients. Nausea, diarrhea, hypokalemia, vomiting, and headache were the most commonly reported adverse events.
"This study was the first report of venetoclax in AML, and as such was a single-agent study," Dr. Letai said. "However, I do not think single-agent use will be common in AML for this drug. I think that venetoclax will be incorporated into combinations with many other agents active in AML."


"Right now, in the elderly setting, it is being combined with either hypomethylating agents (vidaza or decitabine) or low-dose cytarabine, both commonly used in the elderly in AML," he said. "The response rates have been fantastic, around 70%, as reported in abstracts at ASH and ASCO. There will likely be clinical testing of combinations including venetoclax at all stages of AML therapy, including induction, consolidation, salvage. Indeed, some of these trials are already starting. Who knows, perhaps even maintenance? It is well tolerated, so lends itself to combination."

"Genomics and genetics are often equated with personalized medicine, the job of which is to match the right patient with the right drugs," Dr. Letai added. "Venetoclax has so far demonstrated activity in CLL, mantle cell lymphoma, AML. There are no genetic abnormalities related to BCL-2 that would indicate activity in these cancers. If we relied on genetics alone, these would have missed."

"Instead, we and others took a functional approach to identifying BCL-2 dependence in cancers, and thus identifying good targets for venetoclax," he said. "I think that these functional precision-medicine approaches are going to be vital to taking advantage of all the new drugs that are appearing in cancer. If we rely on genomics alone, we will probably miss most of our therapeutic opportunities."

Dr. Fernando Ramos from the University of Leon in Spain, who recently reviewed AML in older adults, told Reuters Health by email, "Venetoclax may be an interesting option for rescue therapy in this patient subset."

"Precision medicine has come a long way," added Dr. Ramos, who was not involved in the study. "Venetoclax may be an interesting partner to azanucleosides in unfit AML patients."

Currently, venetoclax is in phase 2 testing for AML, diffuse large B-cell lymphoma, and non-Hodgkin lymphoma and in phase 3 testing for multiple myeloma.

AbbVie and Genentech funded the study, employed 13 of the 22 authors, and had various relationships with four other authors, including Dr. Letai.


Categories: Clinical Update, Science Update

Post a Comment

Oops!

Oops, you forgot something.

Oops!

The words you entered did not match the given text. Please try again.

53 Comments

Reply www.uggau.org.uk
9:09 AM on November 3, 2016 
This study included patients that were in categories that are difficult to treat.
Reply site
5:35 AM on January 28, 2017 
One of my friend recommended this blog site to me. I love reading blogs., honestly speaking l love this blog post very much. This is simple but very interesting and worth reading. Thank you so much for sharing this here. Make your blog more active with updating new contents.
Reply leather biker jackets for men
7:44 AM on August 11, 2017 
I am really impressed with this blog! Very clear explanation of issues is given and it is open to everyone.
Reply pay for college papers
5:29 PM on October 9, 2017 
Medical science struggle very hard for fighting newly introduced diseases. Doctors are used their expertise to find new solution of diseases. Medicines are prepared with extra care that they cannot disturb other function of patient rather than disease.
Reply
1:48 PM on December 12, 2017 
This site contains valuable information in it. I am really happy with articles quality and presentation. Thanks a lot for keeping great stuff. small cardboard box
Reply Jahon
11:56 AM on December 13, 2017 
In the post is very interesting and informative for me. This post totally related the mom and daughter love for us. I am appreciate in the efforts everyone mom. Thanks for sharing in the post.
business roll stickers printing supplier company in au
Reply i hate you but i love you
3:37 AM on September 24, 2018 
One of my friends recommended this blog site to me. I love reading blogs., honestly speaking l love this blog post very much. I like this post that amazing and interesting. Thanks for share! Visit my home:
quotes about time passinge
Reply net worth
6:38 AM on October 23, 2018 
Because of posts like this I surf the internet and when I found you, the time I felt I was wasting, just turned my thoughts around and now I am thinking I invested my time in something really interesting
Reply Disanva
2:11 AM on November 23, 2018 
That's reall an amazing post. Thanks for letting us know about it.
typing games for kids
Reply Jaime
8:09 AM on January 28, 2019 
I am very impress to after reading venetoclax shows promise in acute myelogenous leukemia. I am appreciate in the work. I really like to it for here. Thanks for sharing in the information. playground mats over grass
Reply Steve john
11:03 AM on January 28, 2019 
i really like your post and i am happy to see your blog.your post is very informative and useful. thanks for sharing the wonderful post.
click here to get rubber mats
Reply samwilliam
11:08 AM on January 28, 2019 
I read this post and get a useful information from this. The information which you share about the myelogenous leukemia is very informative. I appreciate you for sharing this post for the awareness of people from this disease. I must share this with others. Thanks for sharing this all. Keep sharing.
non slip flooring for sale in uk
Reply Edwin W. Best
11:10 AM on February 16, 2019 
Thank u So much For Share information.
download terraria apk
Reply 192.168.l.l
6:54 AM on September 3, 2019 
The photos looks sad. Thank you for sharing the post.
Reply professional paper writing service
11:57 AM on November 26, 2019 
AllAssignmentHelp.com is extraordinary notoriety among students, we express learning with complete data. Our specialists are the mainstay of our administration. These journalists are so flourishing in their training that they try to give a great job on composing assignments. Click https://www.allassignmenthelp.com/us/write-my-research-paper.html
Reply how to use sb game hacker on township
6:17 AM on January 8, 2020 
Here I have compiled a list of some of the most popular Android games that can be hacked with the latest version of SB Game Hacker.
Reply expressing your feelings to someone you love
4:41 PM on March 31, 2020 
expressing your feelings to someone you love
Reply Buy dissertation online
10:54 AM on May 21, 2020 
If we face any disease, we should see a doctor because if we do not do so, our disease will increase, and we have to face many big challenges. So, take care of your health first and then do other works.
Reply Top Gun Jacket
1:37 PM on August 20, 2020 
Great info! I recently came across your blog and have been reading along. I thought I would leave my first comment. I don’t know what to say except that I have.
Reply Glee Cheerios Jacket
8:03 PM on August 27, 2020 
That's reall an amazing post. Thanks for letting us know about it.
0